HS-10382

The chronic myelogenous leukemia treatment market is expected to experience significant growth through 2032, driven by increasing disease prevalence and multiple recent FDA approvals.

TERN-701, an oral BCR-ABL inhibitor for chronic myeloid leukemia, completes dose escalation phase with promising safety profile and molecular responses in heavily pre-treated patients.

Terns Pharmaceuticals announced positive Phase I data for TERN-701, an allosteric BCR-ABL inhibitor, in relapsed/refractory chronic myeloid leukemia (CML).